A Dose-response Study of Dietary Resveratrol on Lipid Metabolism Disorder

PHASE3CompletedINTERVENTIONAL

Enrollment

168

Participants

Timeline

Start Date

May 1, 2021

Primary Completion Date

May 30, 2022

Study Completion Date

September 30, 2022

Conditions

Dyslipidemias

Interventions

DRUG

Mega Resveratrol® capsules

Subjects were orally administered Mega Resveratrol® capsules daily for 8 weeks.

DRUG

Mega Resveratrol® Placebo capsules

Trial Locations (1)

Sun Yat-Sen University, Guangzhou

All Listed Sponsors

lead

Sun Yat-sen University

OTHER